Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.45 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3901703 | 1.00 | F10 (0.47) | F10IRAK4IRAK1MRGPRX1NEK2 | |
| SCHEMBL8285066 | 0.98 | F10 (0.48) | F10IRAK4IRAK1MRGPRX1KDM1A | |
| Trifluoroacetic Acid SCHEMBL3902896 | 0.92 | IRAK4 (0.45) | F10IRAK4IRAK1MEN1NPC1 | |
| Trifluoroacetic Acid SCHEMBL3910303 | 0.92 | IRAK4 (0.45) | F10IRAK4IRAK1MEN1NPC1 | |
| Trifluoroacetic Acid SCHEMBL3903764 | 0.89 | IRAK4 (0.49) | F10IRAK4IRAK1ATRNPC1 | |
| SCHEMBL3905726 | 0.88 | IRAK4 (0.48) | F10IRAK4IRAK1ATRMEN1 | |
| Trifluoroacetic Acid SCHEMBL3898796 | 0.87 | IRAK4 (0.47) | F10IRAK4IRAK1NPC1RAB9A | |
| SCHEMBL8285063 | 0.87 | IRAK4 (0.48) | F10IRAK4IRAK1MEN1NPC1 | |
| Trifluoroacetic Acid SCHEMBL3905869 | 0.85 | IRAK4 (0.47) | F10IRAK4IRAK1 | |
| SCHEMBL8286949 | 0.85 | IRAK4 (0.52) | F10IRAK4IRAK1ATRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511066-B2 | Antithrombotic aromatic ethers | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070027185-A1 | Antithrombotic aromatic ethers | ELILILLY AND COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027185-A1 | Antithrombotic aromatic ethers | F2, F11, TFPI | F10 14/4885IRAK4 1883/4885IRAK1 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.